Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Hereditary Cancer in Clinical Practice volume 21, Article number: 4 (2023)
Triple-negative breast cancer is a heterogeneous molecular subtype of BC. Pathological complete response (pCR) is an important surrogate marker for recurrence-free and overall survival.
Aim of study
The aim of this study was to evaluate clinical and pathological factors that are associated with complete pathological response status in triple-negative breast cancer patients receiving neoadjuvant chemotherapy.
Materials and methods
Eighty triple-negative breast cancer patients who underwent neoadjuvant chemotherapy followed by surgery at Pauls Stradins Clinical University Hospital between January 2018 and January 2020 were retrospectively analysed. Twenty-six patients (32.5%) were BRCA1/2 pathogenic variant carriers.
A total of 32.5% (n = 26) of patients in all study groups and 57.7% (n = 15) of patients with BRCA1/2 pathogenic variants achieved pCR. Forty-seven patients received platinum-based neoadjuvant chemotherapy, and 19 patients (40.4%) achieved complete pathological response. Patients in the pCR group presented with significantly higher Ki-67 scores (p = 0.007), BRCA1/2 pathogenic variants (p = 0.001) and younger age (p = 0.02) than those in the non-pCR group. pCR did not significantly impact recurrence-free survival (RFS) or overall survival (OS). Multivariate analysis revealed that pretreatment N stage (clinical nodal status) was an independent prognostic factor for RFS and OS.
BRCA1 pathogenic variants, high Ki67 score and young age were predictors of pathological complete response, while clinical nodal status predicted survival outcomes in triple-negative breast cancer.
Breast cancer is the most common tumour in women in Latvia and worldwide; moreover, triple-negative breast cancer (TNBC) is diagnosed in 10–15% of all breast cancers and is characterized by rapid growth and shorter survival . In comparison with other molecular subtypes of breast cancer, TNBC is more common in younger women . Chemotherapy is currently the only treatment option for TNBC in Latvia. Anthracycline/taxane-based chemotherapy remains the standard of care systemic therapy for early-stage TNBC. TNBC is more sensitive to chemotherapy than other molecular subtypes, and 30–60% of patients can achieve a pathological complete response (pCR) to neoadjuvant chemotherapy (NAC), which is strongly associated with prolonged survival [2, 3]. Platinum-based NAC has been shown to increase the rates of pCR in TNBC patients compared to standard NAC; however, this treatment regimen has a higher level of toxicity .
Hereditary germline BRCA mutations occur in approximately 10–20% of women with stage I–III TNBC and play an important role in carcinogenesis and in predicting response to chemotherapy in TNBC with a characteristic pattern of DNA gains and losses . Neoadjuvant platinum-based chemotherapy regimens increase the pCR rate by more than 60% in BRCA1-mutated breast cancer .
The aim of this study was to evaluate clinical and pathological factors that are associated with pCR in TNBC after neoadjuvant chemotherapy.
Patients and methods
Of the 130 TNBC patients treated between January 2018 and January 2020 in the Clinic of Oncology, Pauls Stradins Clinical University Hospital (Riga, Latvia), a total of 80 received NAC. Twenty-eight patients with metastatic TNBC and 26 patients with upfront surgery were excluded from the analysis. All patients were female. The clinical and pathological data of patients were collected from medical records and retrospectively analysed. Ethical approval was provided by the Ethics Committee at Latvian University, and the study was performed in accordance with ethical standards.
The clinical TNM stage was evaluated prior to NAC (cTNM) and after surgery (ypTNM). The tumour size and nodal status were evaluated by magnetic resonance imaging (MRI), and distant metastases were detected with CT scans.
Negative oestrogen receptors (ER), progesterone receptors (PgR), Ki67 and HER2 were diagnosed by core needle biopsy prior to NAC. The expression of ER, PrR and Ki67 was evaluated using immunohistochemistry (ICH) scoring of the percentage of cells with positive nuclear staining (1–100%). ER and PR were considered negative if nuclear staining was < 1%. Ki67 expression was considered low when < 50% and high when ≥ 50% stained cells were detected. HER2 was scored as 0 to 3 + by IHC. HER2 positivity was defined by an IHC score of 3 + or by HER2 gene amplification from FISH.
The response to NAC was evaluated by a pathologist following surgery. Pathological response to NAC was evaluated by the Miller-Payne grading system from I (no response to NAC) to V (complete pathological response). In our study, pCR was defined as the absence of any residual invasive cancer cells (ypT0N0M0).
Genomic DNA was isolated from peripheral blood cells and screened for the most common BRCA1 and BRCA2 pathogenic variants in Latvia (BRCA1: c.68_68del, c.181 T > G, c.4035delA, c.5266dupC, c.1961del, c.3700–3704, c.3756–3759, c.5117G > A, c.4675G > A, c.843_846del; BRCA2: c.643G > T/A, c.646del, c.658_659del, c.5946del, c1813dupA). Types of pathogenic variants are listed in Table 1.
Patients were treated with platinum-containing and anthracycline- and taxane-based regimens. Regimens are listed in Table 2. The choice of chemotherapy regimen was made by a medical oncologist.
Recurrence-free survival (RFS) was defined as the time from surgery to detection of local relapse or metastatic disease or death attributed to disease progression. Overall survival (OS) was defined as the time from surgery to death.
Associations between pCR, BRCA and clinicopathological characteristics were assessed with a Mann‒Whitney U test, Fisher’s exact test or Chi-square test. Kaplan‒Meier and log-rank tests were used to calculate survival differences. All analyses were performed using MedCalc statistical software, version 16.4.8 (MedCalc Software, Ostend, Belgium). P < 0.05 was considered to indicate statistical significance.
Eighty patients with TNBC received neoadjuvant chemotherapy at Pauls Stradins Clinical University Hospital (Riga, Latvia) between January 2018 and January 2020. Twenty-six patients (32.5%) had BRCA1/2 pathogenic variants.
Twenty-six patients (32.5%) (n = 80) achieved pCR after NAC.
A total of 57.7% of BRCA-mutated patients and 40.4% of patients who received platinum-based NAC achieved pCR (Table 2).
Pathological complete response
There was a statistically significant correlation between pCR and BRCA1 pathogenic variants, high Ki67 levels and young age. pCR was detected in 57.7% vs. 20.4% (p = 0.001) in BRCA mutated vs. BRCA wild type; 47.5% vs. 17.5% (p = 0.007) in High Ki67 vs. low Ki67; 58.8% vs. 25.4% (p = 0.02) in age 20–39 vs. ≥ 40, respectively. The pCR rate was 40.4% vs. 21.2% (p = NS) in platinum-based vs. conventional NAC; 50% vs. 16.7% (p = NS) in T1 vs. T4; and 38.5% vs. 26.8% (p = NS) in N0 vs. N + , respectively (Table 3).
During the follow-up period (median 33 months, 95% CI 26–38 months), 15 patients progressed, and 9 died. In patients with recurrence, the mRFS was 15 months (10–41 months, 95% CI 11.6–25.3 months).
The mRFS in the study group (n = 80) was not met. The 1-y RFS was 95%, 2-y RFS was 84.2%, 3-y RFS was 80.5%, and 4-y RFS was 77.4%. mOS was also not met. The 1-y-OS was 100%, 2-y-OS was 96.1%, 3-y-OS was 88.7%, and 4-y-OS was 85.3%.
RFS and OS differences in the pCR vs. non-pCR groups were not statistically significant. The hazard ratio for recurrence-free survival was 2.36 (95% CI 0.79–7.07; p = 0.123), and the HR for overall survival (OS) was 2.13 (95% CI 0.46–9.78; p = 0.32) (Fig. 1).
RFS was correlated with cT stage (mRFS in cT4 was 25 months; in other groups, mRFS was not met, p = 0.0067), cN stage (mRFS in cN2-3 was 31 months; in other groups, mRFS was not met, p = 0.0015), ypT stage (p = 0.0067), and ypN stage (p = 0.023).cN and ypN stage were correlated with longer OS – mOS in cN2-3 was 49 months vs. not met in cN0 (p = 0.007), but ypN0 vs. ypN + demonstrated HR 0.12 (95% CI 0.03–0.51; p = 0.003).cT, cN, ypT, and ypN stage were independent factors for RFS in univariate analysis, but cN stage was independent factor in multivariate analysis. cT, cN, ypT, ypN stage and platinum-based NAC were independent factors for OS in univariate analysis, but cN stage was independent factor in multivariate analysis (Table 4).
Hereditary breast cancer
In the current cohort, 26 patients with germline BRCA1 or BRCA2 gene pathogenic variants were identified. Patients with BRCA pathogenic variants were younger (mean 44 years vs. 55 years, p = 0.017) and presented a better response to NAC (pCR 55.6% vs. 20.9%, p = 0.0003). In this group, platinum-based NAC was more frequently used (92.3% vs. 40.9%, p = 0.0002), and mastectomy was the preferred surgery option (p = 0.0001). Statistically significant differences in CA15-3, CA125, platelet count, Ki67 score, primary tumour size, clinical TNM stage and recurrence were not observed (Table 5).
Our findings from the retrospective study at Pauls Stradins Clinical University Hospital suggested that BRCA pathogenic variants and high Ki67 expression are associated with a higher incidence of complete pathological response after neoadjuvant chemotherapy.
As one of the prognostic biomarkers in the treatment of breast cancer, the Ki-67 index has been demonstrated to be associated with tumour chemosensitivity and associated with a more frequent pCR, while pCR improves patient survival . In a study by Nakashoji, a high Ki67 score was observed in 83% of patients in the pCR group vs. 46% in the non-pCR group . In this study, 50% of patients receiving neoadjuvant chemotherapy had a Ki-67 index above 50%, and 47.5% of these patients achieved a pCR. Additionally, pCR was observed more frequently in patients with BRCA 1 or 2 pathogenic variants (57.7%).
The addition of platinum to NAC regimens showed promising results, but their use remains controversial. The meta-analysis performed by Li and his colleagues shows that the addition of platinum to standard chemotherapy increases the probability of pCR by 13.2% (49.1% in the platinum-based NAC group vs. 35.9% in the standard NAC group) , but in a study published in 2018 by Gass and colleagues, pCR reached 50% after platinum/taxane treatment (vs. 41.8% after anthracycline/taxane treatment) . Similarly, in the GeparSixto trial, carboplatin-based NACT increased pCR rates – 53.2% vs. 36.9% (p = 0.005) , while our analysis failed to support these findings in this retrospective cohort – 40.4% in platinum-based NAC vs. 21.2% in nonplatinum-based NAC, but this was not statistically significant in the adjusted analysis.
In patients with TNBC, a pCR has been observed to be a strong indicator for better outcome. If pCR is achieved as a result of NAC, survival is similar to survival in other, more favourable, molecular subtypes of BC, but in the case of a partial response to NAC, short survival and fast recurrence are commonly observed . In a study by Gass and colleagues, pCR was significantly related to increased RFS and OS . Two other randomized trials, the CALB40603 trial and BrighTNess study, demonstrated significant increases in pCR rates and relapse-free survival in TNBC with the addition of carboplatin to taxane- and anthracycline-containing NACT [11, 12]. The BrighTNess study identified significant improvements in RFS for patients with pCR vs. non-pCR both in patients with an identified germline pathogenic variant in BRCA1 or BRCA2 (HR 0.14) and in BRCA wildtype patients (HR 0.29) . Our study confirmed these data – patients with pCR experienced increased RFS (7.7% relapsed in pCR vs. 24.1% in non-pCR) and OS (3.8% died in pCR vs. 14.8% in non-pCR) than patients with partial response, but the result was not statistically significant, which may be based on the low number of patients in the study group.
Regarding decreased survival rates, patients with incomplete response to NAC are candidates for postoperative systemic treatment, such as chemotherapy or innovative drugs, to improve disease control and survival. Since 2017, when Masud and colleagues published results from the CREATE-X study with colleagues, it is known that patients with residual disease following NAC and surgery may benefit from adjuvant chemotherapy with capecitabine . Capecitabine was not reimbursed in Latvia in the current time period, and only 4 patients received adjuvant treatment in the non-pCR group.
In our study, a comparison between TNBC patients with BRCA pathogenic variants and sporadic cancer patients was also performed. As expected, patients with BRCA pathogenic variants were significantly younger, and increased pathological response to NAC was observed. According to the Miller-Payne grading system, grade I-II response (no response or weak response to NAC) was not observed (0%) in the BRCA-mutated group compared to 34.7% in the sporadic TNBC group, but pCR was observed in 57.7% vs. 20.4%, respectively. Patients with BRCA-mutated TNBC were more often treated with platinum-based NAC, and the mastectomy rate was significantly higher. Similar findings were published by Kedzierawski and colleagues – the rate of pCR in BRCA-mutated TNBC was 54.2% vs. 40.3% .
This study has limitations that should be mentioned. First, it was a retrospective study with a relative deficiency of patients in subgroups, which could have influenced the bias of the obtained results. The collected sample size in two years was small, which could be improved in further studies by adding patients from the next years. Second, the study group was heterogeneous – different chemotherapy regimens used, clinical and pathological findings, surgery types, and BRCA status (mutated, wild type or unknown) could also impact the results. In our study, ten different platinum-based chemotherapy regimens with different counts of chemotherapy agents were used. In such a small study, it is difficult to refer to the results, but we observed a benefit of adding platinum salts in patients with BRCA1/2 pathogenic variants. Larger randomized trials have already been published addressing the efficacy of platinum-based NAC and its correlation with pCR and survival in TNBC; therefore, our retrospective study adds real-life experience from a single university hospital to the current knowledge despite its limitations. Further studies are needed to confirm the current results.
This retrospective study observed higher pCR rates after neoadjuvant therapy in TNBC patients with younger age, higher Ki67 score and BRCA1 pathogenic variants. Additionally, BRCA pathogenic variants were associated with young age, increased response to NAC, higher rate of pCR, increased mastectomy rate and frequent use of platinum-based neoadjuvant chemotherapy.
This study did not confirm the impact of platinum-based NAC on survival in TNBC due to the small patient number and heterogeneous list of chemotherapy regimens used.
Availability of data and materials
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Complete pathological response
Triple-negative breast cancer
Bianchini G, Balko JM, IMayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13:674–90. https://doi.org/10.1038/nrclinonc.2016.66.
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81. https://doi.org/10.1200/JCO.2007.14.4147.
Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges. Cancers. 2020;12(6):1404. https://doi.org/10.3390/cancers12061404.
von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, Zahm DM, Kümmel S, Eidtmann H, Klare P, Huober J, Costa S, Tesch H, Hanusch C, Hilfrich J, Khandan F, Fasching PA, Sinn BV, Engels K, Mehta K, Nekljudova V, Untch M. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747–56. https://doi.org/10.1016/S1470-2045(14)70160-3.
Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, Wenstrup RJ, Sandbach JF. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787–95. https://doi.org/10.1002/cncr.26576.
Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, Jakubowicz J, Cybulski C, Wisniowski R, Godlewski D, Lubinski J, Narod SA. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014;147(2):401–5. https://doi.org/10.1007/s10549-014-3100-x.
Nakashoji A, Matsui A, Nagayama A, Iwata Y, Sasahara M, Murata Y. Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Oncol Lett. 2017;14(4):4135–41. https://doi.org/10.3892/ol.2017.6692.
Li ZY, Zhang Z, Cao XZ, Feng Y, Ren SS. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis. J Int Med Res. 2020;48(10):300060520964340. https://doi.org/10.1177/0300060520964340.
Huang M, O’Shaughnessy J, Zhao J, Haiderali A, Cortés J, Ramsey SD, Briggs A, Hu P, Karantza V, Aktan G, Qi CZ, Gu C, Xie J, Yuan M, Cook J, Untch M, Schmid P, Fasching PA. Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis. Cancer Res. 2020;80(24):5427–34. https://doi.org/10.1158/0008-5472.CAN-20-1792.
Gass P, Lux MP, Rauh C, Hein A, Bani MR, Fiessler C, Hartmann A, Häberle L, Pretscher J, Erber R, Wachter DL, Schulz-Wendtland R, Beckmann MW, Fasching PA, Wunderle M. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer. 2018;18(1):1051. https://doi.org/10.1186/s12885-018-4925-1.
Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, Somlo G, Port ER, Ma C, Kuzma C, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Hudis CA, Winer EP, Partridge A, Hyslop T, Carey LA, Perou CM, Sikov WM. CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer. J Clin Oncol. 2022;40(12):1323–34. https://doi.org/10.1200/JCO.21.01506.
Geyer CE, Sikov WM, Huober J, Rugo HS, Wolmark N, O’Shaughnessy J, Maag D, Untch M, Golshan M, Lorenzo JP, Metzger O, Dunbar M, Symmans WF, Rastogi P, Sohn JH, Young R, Wright GS, Harkness C, McIntyre K, Yardley D, Loibl S. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Ann Oncol. 2022;33(4):384–94. https://doi.org/10.1016/j.annonc.2022.01.009.
Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59. https://doi.org/10.1056/NEJMoa1612645.
Kedzierawski P, Macek P, Ciepiela I, Kowalik A, Gozdz S. Evaluation of complete pathological regression after neoadjuvant chemotherapy in triple-negative breast cancer patients with brca1 founder mutation Aided Bayesian A/B testing approach. Diagnostics. 2021;11(7):1144. https://doi.org/10.3390/diagnostics11071144.
Ethics approval and consent to participate
This retrospective evaluation was approved by the Latvia University Ethical Committee (Nr.13–32/42–1.04.2022).
Consent for publication
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sivina, E., Blumberga, L., Purkalne, G. et al. Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience. Hered Cancer Clin Pract 21, 4 (2023). https://doi.org/10.1186/s13053-023-00249-1
- Triple-negative cancer
- Neoadjuvant chemotherapy
- Complete pathological response